Newsroom

LOTTE BIOLOGICS announced that it successfully concluded its participation in DCAT Week 2025, held in New York, USA, from March 17 to 20, while exploring business opportunities.

During the event, LOTTE BIOLOGICS held meetings with numerous companies, including global big pharma and biotech firms, to discuss potential collaborations. The company also actively pursued partnership expansions through follow-up meetings with select companies.

At this year’s event, LOTTE BIOLOGICS also introduced the company through a large promotional banner displayed at the Lotte New York Palace Hotel. In particular, they highlighted their geographical advantage with a dual site strategy spanning the U.S. and Korea, its ADC manufacturing capabilities, and the quality competitiveness of the new Songdo Bio Campus currently under construction.

LOTTE BIOLOGICS plans to commence operations at its ADC manufacturing facility within the Syracuse Bio Campus this year. Additionally, it is accelerating efforts to secure a leading position in the global ADC market by leveraging SoluFlex-Link, its proprietary ADC platform technology unveiled at this year’s J.P. Morgan Healthcare Conference, as a key sales point.

Through these initiatives, LOTTE BIOLOGICS aims to enhance its brand recognition as a global CDMO while expanding its modality offerings and driving substantial order acquisitions.

A LOTTE BIOLOGICS representative stated, "Through numerous partnering meetings, we are striving to showcase our differentiated competitiveness and attract potential partners. This event has not only helped raise our brand awareness but also served as an opportunity to expand our collaboration network with major pharmaceutical companies worldwide."